MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Pacira Pharmaceuticals Inc-DE

Avatud

SektorTervishoid

20.66 4.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.52

Max

20.68

Põhinäitajad

By Trading Economics

Sissetulek

10M

5.4M

Müük

-1.6M

180M

P/E

Sektori keskmine

40.766

89.037

Kasumimarginaal

3.026

Töötajad

788

EBITDA

5.1M

34M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+53.94% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-173M

824M

Eelmine avamishind

16

Eelmine sulgemishind

20.66

Uudiste sentiment

By Acuity

63%

37%

321 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2025, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Võrdlus sarnastega

Hinnamuutus

Pacira Pharmaceuticals Inc-DE Prognoos

Hinnasiht

By TipRanks

53.94% tõus

12 kuu keskmine prognoos

Keskmine 29.71 USD  53.94%

Kõrge 38 USD

Madal 23 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Pacira Pharmaceuticals Inc-DE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

2

Hoia

1

Müü

Tehniline skoor

By Trading Central

24.83 / 26.38Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

321 / 360 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat